Pharmaceutical

Janssen’s Talvey adds European approval on top of its US authorisation

Janssen’s bispecific antibody received conditional approval as a subcutaneous therapy based on Phase I/II trial data.

Aug 22, 2023 - 20:00
Janssen’s Talvey adds European approval on top of its US authorisation
Janssen’s bispecific antibody received conditional approval as a subcutaneous therapy based on Phase I/II trial data.
Read the original article

Tags:

Previous Article

Halia plans two trials testing its anti-inflammatory lead candidate

Next Article

How a flexible FSP model fills the talent gap

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

American Cancer Society expands lung cancer screening guidelines for cigarette smokers

American Cancer Society expands lung cancer screening g...

Nov 1, 2023

House GOP inquiry over gain-of-function research targets a scientific giant

House GOP inquiry over gain-of-function research target...

Jun 22, 2023

STAT+: Biotech’s trade secrets face growing threat from foreign influences, science leaders warn

STAT+: Biotech’s trade secrets face growing threat from...

Jun 6, 2023